Prevents pregnancy. ANDA 202962, held by Novast Labs. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 202962 (Chabelina Fe), held by Novast Labs, was first approved by FDA on Apr 15, 2020, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Tilia Fe is indicated for the prevention of pregnancy in women who elect to use combined oral contraceptives as a method of contraception. Tilia Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to combined oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Tilia Fe should be used for the treatment of acne only if the patient desires a combined oral contraceptive for birth control and plans to stay on it for at least 6 months. Combined oral contraceptives are highly effective for pregnancy prevention.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 15, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Chabelina Fe0.02MG,0.03MG,0.035MG;1MG,1MG,1MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Apr 29, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 18, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 15, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters